BACKGROUND: Injection drug users (IDUs) are at high-risk for hepatitis B virus (HBV) and HIV. Due to concerns about non-adherence to multi-dose vaccine regimens however, IDUs are severely under-immunized against HBV and have been excluded from phase III trials of multi-dose candidate HIV vaccines in the United States. METHODS: Through a randomized controlled trial, we compared the effectiveness of monetary incentives versus outreach to improve IDUs' adherence to the 3-dose hepatitis B vaccine. In 1998-1999, HBV-susceptible IDUs were recruited from San Francisco streets. Eligible participants received their first dose of vaccine and were randomized to either receive monthly monetary incentives (n=48) or maintain weekly contact with an outreach worker (n=48) during the 6-month vaccine series. RESULTS: All 3 doses of vaccine were received by 33 (69%) of IDUs in the monetary incentive arm and 11 (23%) in the outreach arm (odds ratio=13.8; 95% confidence interval, 2.9, 128; P<0.0001). In a multivariate model, receiving monetary incentives was independently associated with vaccine completion (AOR=10.3; 95% CI=3.7, 29.0). CONCLUSIONS: Among IDUs, monetary incentives are superior to outreach in achieving adherence to the multi-dose hepatitis B vaccine series. Monetary incentives may be adapted to future multi-dose candidate HIV vaccine trials in IDUs.
RCT Entities:
BACKGROUND: Injection drug users (IDUs) are at high-risk for hepatitis B virus (HBV) and HIV. Due to concerns about non-adherence to multi-dose vaccine regimens however, IDUs are severely under-immunized against HBV and have been excluded from phase III trials of multi-dose candidate HIV vaccines in the United States. METHODS: Through a randomized controlled trial, we compared the effectiveness of monetary incentives versus outreach to improve IDUs' adherence to the 3-dose hepatitis B vaccine. In 1998-1999, HBV-susceptible IDUs were recruited from San Francisco streets. Eligible participants received their first dose of vaccine and were randomized to either receive monthly monetary incentives (n=48) or maintain weekly contact with an outreach worker (n=48) during the 6-month vaccine series. RESULTS:All 3 doses of vaccine were received by 33 (69%) of IDUs in the monetary incentive arm and 11 (23%) in the outreach arm (odds ratio=13.8; 95% confidence interval, 2.9, 128; P<0.0001). In a multivariate model, receiving monetary incentives was independently associated with vaccine completion (AOR=10.3; 95% CI=3.7, 29.0). CONCLUSIONS: Among IDUs, monetary incentives are superior to outreach in achieving adherence to the multi-dose hepatitis B vaccine series. Monetary incentives may be adapted to future multi-dose candidate HIV vaccine trials in IDUs.
Authors: Evan S Herrmann; Alexis K Matusiewicz; Maxine L Stitzer; Stephen T Higgins; Stacey C Sigmon; Sarah H Heil Journal: J Subst Abuse Treat Date: 2016-06-24
Authors: Ricky N Bluthenthal; D Phuong Do; Brian Finch; Alexis Martinez; Brian R Edlin; Alex H Kral Journal: J Urban Health Date: 2007-07-27 Impact factor: 3.671
Authors: Eric M VanEpps; Andrea B Troxel; Elizabeth Villamil; Kathryn A Saulsgiver; Jingsan Zhu; Jo-Yu Chin; Jacqueline Matson; Joseph Anarella; Patrick Roohan; Foster Gesten; Kevin G Volpp Journal: Am J Health Promot Date: 2018-02-01
Authors: Braden K Mogler; Suzanne B Shu; Craig R Fox; Noah J Goldstein; Ronald G Victor; José J Escarce; Martin F Shapiro Journal: J Gen Intern Med Date: 2012-11-15 Impact factor: 5.128